Key facts
- Oncolytics Biotech reports positive initial preclinical findings for pelareorep.
- Findings support further evaluation of pelareorep in combination with RAS-targeted approaches.
- Early results are from solid tumor models and suggest potential for pancreatic and colorectal cancer.
- A full dataset is planned for presentation in 2026.
Oncolytics Biotech is investigating pelareorep, an investigational cancer therapeutic, in combination with other treatments. These preclinical results suggest a potential pathway for its use in specific types of cancer, particularly those involving RAS mutations, which are common in pancreatic and colorectal cancers.